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Yasuhiro Takagi, MD, PHD,* Yoshiki Matsumura, MD, PHD,* Minoru Yoshiyama, MD, PHD,*
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Objectives We sought to evaluate the effects of beta-blocker therapy on regional and global myocardial mechanics in addi-
tion to ventricular synchrony in patients with heart failure and normal QRS by using tissue Doppler and strain
echocardiography.
Background It is unknown whether beta-blocker therapy can influence mechanical synchrony.
Methods Conventional and strain echocardiography were performed in 15 healthy age-matched volunteers and in 25 pa-
tients with idiopathic dilated cardiomyopathy (IDC). Of these, 15 IDC patients on standard heart failure therapy
were studied prior to and at 1 and 6 months after initiation of carvedilol therapy and compared to the controls.
Results There was significant mechanical dyssynchrony in IDC compared with control patients. Patients placed on carve-
dilol demonstrated a significant decrease in the inferoseptal to lateral wall delay in peak strain (normalized to
the R-R interval) between baseline and 1 month and between baseline and 6 months. Similarly, global time to
peak segmental strain (455  51 ms vs. 423  59 ms, respectively, p  0.02, and 455  51 ms vs. 415 
50 ms, respectively, p  0.01) and the coefficient of variation of the time to peak segmental strain decreased
(17  4% vs. 15  5%, respectively, p  0.02, and 17  4% vs. 14  5%, respectively, p  0.03), from base-
line to 1 month and between baseline and 6 months, respectively. Global strain significantly increased from
baseline to 1 month (8.2  1.8 to 10.4  3.9, respectively, p  0.01) and between baseline and 6 months
(8.2  1.8% to 12.0  3.2%, respectively, p  0.008). Improvements in left ventricular ejection fraction and
reverse remodeling were coincident with reductions in mechanical dyssynchrony.
Conclusions The use of carvedilol improves contractile function and dyssynchrony in heart failure patients with normal QRS.
(J Am Coll Cardiol 2007;49:778–83) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.081s
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bsignificant proportion of patients with heart failure (HF)
evelop conduction abnormalities (1). Intraventricular dys-
ynchrony appears to play a major pathophysiologic role in
F, as suggested by the substantial clinical improvements
bserved after cardiac resynchronization therapy (CRT)
hrough biventricular pacing (2,3). As a result, CRT has
merged as a promising treatment for medically refractory
eart failure. Published data suggest that CRT improves
atient symptom and quality of life, induces reverse remod-
ling, positively impacts neurohumoral pathways, and may
mprove outcomes and survival (4,5). The presence of
rom the *Department of Internal Medicine and Cardiology, Osaka City University
chool of Medicine, Osaka, Japan; †Division of Cardiology, John Hopkins Univer-
ity, Baltimore, Maryland; and the ‡Department of Cardiology, Osaka Ekisaikai
ospital, Osaka, Japan.i
Manuscript received January 17, 2006; revised manuscript received April 19, 2006,
ccepted May 22, 2006.ignificant intraventricular synchrony appears to predict a
atient’s response to CRT (5,6).
All large CRT clinical trials primarily enrolled patients
ith significant prolongation of the QRS complex (120
s) (7,8). However, more recent data demonstrate that a
roportion of HF patients with narrow QRS complexes also
emonstrate significant intraventricular dyssynchrony as
etected by tissue Doppler echocardiography (TDE) (9)
here is a growing clinical conundrum as to whether
atients with HF and narrow QRS complexes but signifi-
ant ventricular dyssynchrony on TDE (heart failure 
arrow QRS [HF-N]) would benefit from CRT. Decisions
o treat HF-N patients with CRT devices have obvious
linical and economic implications.
Clinical trials have shown that medical therapy (e.g.,
eta-blockers) can induce morphologic reverse remodeling
n patients with HF. However, it is unknown whether
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February 20, 2007:778–83 Resynchronization With Beta-Blockersedical therapy can influence mechanical synchrony. Intu-
tively, beta-blocker therapy may worsen conduction abnor-
alities in patients and, therefore, dyssynchrony. Intraven-
ricular synchrony is most commonly assessed using TDE,
hich is used to measure local tissue velocities and can
ccurately depict regional myocardial mechanical activity.
issue Doppler-derived strain echocardiography (SE) de-
icts regional deformation and may be superior to TDE
ecause it is less susceptible to translational and tethering
rtifacts (10). Accordingly, the present study sought to
xamine changes in ventricular function and mechanical
ynchrony using SE in HF-N patients receiving carvedilol
herapy.
ethods
tudy group. All patients and healthy volunteers provided
nformed consent, and the protocol was approved by the
ommittee on clinical investigation of Osaka City Univer-
ity Institutional Review Board. We prospectively and
onsecutively enrolled patients with idiopathic dilated car-
iomyopathy (IDC). Inclusion criteria were ejection frac-
ion (EF) 40%, narrow QRS 120 ms, normal sinus
hythm, no significant coronary artery stenosis confirmed by
oronary angiography, and no prior administration of beta-
locker therapy. We excluded patients with significant
alvular heart disease, a history of cardiac surgery, pace-
aker implantation, congenital heart disease, secondary
ardiomyopathy, atrial fibrillation, and QRS width exceed-
ng 120 ms. All patients were clinically stable and on stable
edical therapy, including angiotensin-converting enzyme
nhibitor or angiotensin II receptor blockades and diuretics.
ll medication doses were optimized before enrollment and
emained unchanged during the study. Healthy volunteers
ere solicited via campus advertisements and were individ-
als with no cardiac history, who were not on any cardio-
ctive medications (including carvedilol), and who had a
ormal screening echo-Doppler examination. Controls were
ge-matched such that there was one control for every
atient.
eta-blocker therapy. Carvedilol was initiated after initial
chocardiographic examination in 15 patients with IDC.
he starting dose was 2.5 or 5 mg/day, which was titrated
pwards to a target dose of 20 mg/day or maximum
olerated dose. The control group subjects did not receive
ny medications.
chocardiography. All patients and controls underwent
tandard, comprehensive 2-dimensional (2D) and Doppler
chocardiography at enrollment. Additionally, 15 patients
ith IDC were studied at 1 and 6 months after the
nitiation of carvedilol therapy. Left ventricular (LV) end-
iastolic volume, end-systolic volume, and EF (biplane
impson’s formula) were determined. All patients under-
ent TDE and SE at the same time points as conventional
chocardiography. All age-matched healthy volunteers un-
erwent standard, comprehensive 2D and Doppler echocar- siography, TDE, and SE at a
ingle time point. All imaging
as performed using a Vivid 7
ltrasound system (GE Ultra-
ound, Horten, Norway). Stan-
ard views were used for conven-
ional echocardiography. For
DE and SE, single walls were
maged in 3 apical views, at high
rame rates (170 to 200 frames/s)
sing a narrow sector angle with
he wall parallel to the ultrasound
eam (10). At least 3 consecutive
eats were obtained, and the im-
ges were stored digitally for of-
ine analysis. All TDE and SE
arameters were analyzed per
egment using a standard 12-
egment (American Society of
chocardiography) model. A
train offset length of 8 mm was
sed for all measurements. Sys-
olic strain tracings from 3 car-
iac cycles were obtained of each
egment and averaged to yield a
nal strain curve. Peak systolic
train (segmental ) and time
rom the R-wave of the ECG
race to peak systolic strain (seg-
ental T) were measured on
he averaged strain curve of each
egment. All segmental T val-
es were corrected for the heart
ate using Bazett’s formula to avoid the confounding influ-
nce of changes in heart rate during carvedilol therapy.
egmental  values were averaged over the course of 12
egments to yield a global  value (global ). The coefficient
f variation of segmental  values (CV) was used as an
ndex of heterogeneity of segmental mechanical contraction.
he CV was obtained by dividing the standard deviation
y the mean of segmental  values. Segmental T values
ere averaged over the course of 12 segments to yield a
lobal T value (global T). The coefficient of variation of
egmental T (CVT) was used as a measure of intraven-
ricular dyssynchrony. The CVT was calculated by dividing
he standard deviation by the mean of segmental T values.
tatistics. All values were expressed as mean  SD. The
riedman test was used to compare the 3 time points,
ollowed by the Wilcoxon signed-rank test in case of
ignificance. A value of p  0.05 was considered to indicate
tatistical significance. Simple comparison-wise p values
erived from the Wilcoxon signed-rank test are reported in
he tables and figures. Interobserver and intraobserver vari-
bility for both segmental T and segmental  were mea-
ured by analysis of 4 randomly selected patients (144
Abbreviations
and Acronyms
CV  coefficient of
variation
CV  coefficient of
variation of segmental 
values
CVT  coefficient of
variation of segmental T
global   averaged
segmental strain values
over 12 segments
global T  averaged
segmental T values over
12 segments
HF  heart failure
HF-N  heart failure with
narrow QRS complex
(<120 ms)
IDC  idiopathic dilated
cardiomyopathy
SE  tissue Doppler
derived strain
echocardiography
segmental   peak
systolic strain in a segment
segmental T  time from
the R-wave of the
electrocardiogram trace to
peak systolic strain in a
particular segment
TDE  tissue Doppler
echocardiographyegments) and 4 randomly selected healthy volunteers (48
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Resynchronization With Beta-Blockers February 20, 2007:778–83egments) by 2 independent blinded observers. All results
ere compared by linear least-squares regression analysis.
imits-of-agreement analysis by the methods of Bland and
ltman also was performed.
esults
e enrolled 25 patients with IDC and 15 healthy controls.
f these, 19 patients were enrolled consecutively, whereas
0 additional patients were enrolled later. Four patients did
ot complete the study protocol (1 died during the follow-
p, 1 developed left bundle branch block during the follow-
p, and 2 were lost to follow-up). Therefore, cross-sectional
ata were available in 25 patients with IDC and 15 control
atients. Longitudinal data were available from 15 patients
ith IDC. Baseline characteristics of the patients with IDC
ho were followed longitudinally are given in Table 1. The
ean maintenance dose of carvedilol was 11  6 mg/day.
emodynamic and echocardiographic parameters. He-
odynamic and echocardiographic data are summarized in
able 2. There was no significant change in systolic and
iastolic blood pressures during the study. There was
ignificant decrease in heart rates from baseline to 1 month
84  12 beats/min vs. 72  9 beats/min, respectively, p 
.001) with no further significant change at 6 months.
There were no significant reductions in LV end-diastolic
nd end-systolic volumes at 1 month. However, there were
ignificant reductions in end-diastolic (193  70 ml vs.
56  68 ml, respectively, p  0.008) and end-systolic
olumes (140  58 ml vs. 105  65 ml, respectively, p 
.006) between baseline and 6 months.
Although there was a nonsignificant trend toward an
ncrease in left ventricular ejection fraction between baseline
nd 1 month (28  6% vs. 31  7%, p  0.06), there was
significant increase in left ventricular ejection fraction
etween baseline and 6 months (28  6% vs. 37  10%,
espectively, p  0.004).
aseline Characteristics
Table 1 Baseline Characteristics
Patient # Age, yrs Gender SBP DBP HR
1 49 M 92 64 84
2 75 F 86 56 80
3 29 M 102 68 96
4 65 M 120 86 80
5 31 M 110 80 88
6 66 M 122 76 64
7 53 M 110 76 88
8 72 M 110 60 80
9 46 M 114 76 92
10 65 F 102 64 72
11 75 F 118 66 86
12 69 M 94 60 88
13 58 F 84 54 60
14 55 F 120 72 96
15 70 F 94 60 69CEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; BSA  body sur
ressure; F  female; HR  heart rate; M  male; SBP  systolic blood pressure.train echocardiography. There was significant dyssyn-
hrony in the IDC patients with narrow QRS complexes
n  25) compared with the normal controls (n  15).
lobal T was 457  56 ms versus 348  24 ms (p 
.0001), CV segmental T was 18  4% versus 7  3%
p  0.0001), global  was 8.1  1.8% versus 18.5 
.3% (p  0.0001), and CV segmental  was 43  10%
ersus 14  3% (p  0.0001), respectively (IDC vs.
ontrols). These data confirm the presence of dyssynchrony
n IDC patients with narrow QRS complex compared with
ormal healthy volunteers.
Figure 1 displays representative myocardial strains at the
V midinferoseptal and midlateral segments at baseline, 1
onth, and 6 months. There was a significant decrease in
he inferoseptal to lateral wall delay in segmental T
etween baseline and 1 month (103  51 ms vs. 70  45
s, respectively, p  0.02) and baseline and 6 months
103  51 ms vs. 51  46 ms, respectively, p  0.002).
Table 3 demonstrates EF and SE parameters in healthy
olunteers and the temporal changes in patients with IDC.
he EF and all SE parameters in healthy volunteers were
ignificantly different from those in patients with IDC at
aseline, 1 month, and 6 months. In patients with IDC, there
BSA CAD on CAG ACEI or ARB Digoxin Diuretics
.90 No Yes No Yes
.25 No Yes No Yes
.18 No Yes No Yes
.63 No Yes No Yes
.84 No Yes No Yes
.61 No Yes No Yes
.80 No Yes No Yes
.56 No Yes No Yes
.95 No Yes No Yes
.34 No Yes No Yes
.45 No Yes No Yes
.49 No Yes No Yes
.36 No Yes No Yes
.59 No Yes No Yes
.54 No Yes No Yes
emodynamic and Echocardiographic Parameters
Table 2 Hemodynamic and Echocardiographic Parameters
Baseline 1 Month 6 Months
Hemodynamic parameters
SBP (mm Hg) 105 13 103 11 109 17
DBP (mm Hg) 68 9 64 7 66 11
HR (beats/min) 84 12 72 9* 70 8*
Echocardiographic parameters
EDV (ml) 193 70 186 76 156 68*
ESV (ml) 140 59 135 67 104 65*
EF (%) 28 6 31 7 37 10*
alues are mean  SD. *p  0.05 versus baseline.
DBP  diastolic blood pressure; EDV  end-diastolic volume; EF  ejection fraction; ESV 
nd-systolic volume; HR  heart rate; SBP  systolic blood pressure.1
1
2
1
1
1
1
1
1
1
1
1
1
1
1face area; CAD  coronary artery disease; CAG  coronary angiography; DBP  diastolic blood
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February 20, 2007:778–83 Resynchronization With Beta-Blockersas a significant decrease in global T from baseline to 1
onth (455 51 ms vs. 423 59 ms, respectively, p 0.02),
nd between baseline and 6 months (455  51 ms vs. 415 
0 ms, respectively, p 0.01). There were similar decreases in
V segmental T between baseline and 1 month (17 4% vs.
5  5%, respectively, p  0.02) and between baseline and 6
onths (17  4% vs. 14  5%, respectively, p  0.03).
Global  was significantly reduced in all subjects at
aseline (mean global   8.2  1.8%). There was a
ignificant increase in global  from baseline to 1 month
8.2  1.8% to 10.4  3.9%, respectively, p  0.01) and
etween baseline and 6 months (8.2  1.8% to 12.0 
Figure 1 Representative Traces of Myocardial Strains
(Top) Myocardial strains of the left ventricular midinferoseptal segment: left panel
dial strains of the left ventricular midlateral segment. Inferoseptal to lateral wall d
at baseline, 2 ms at 1 month, and 3 ms at 6 months..2%, respectively, p  0.008). In contrast, there was no aignificant change in CV segmental  between baseline and
month (44  12% vs. 47  22%, respectively, p  0.38).
owever, CV segmental  decreased significantly from
aseline/1 month to 6 months (44  12%/47 22% vs. 33
15%, respectively, p  0.03). Table 3 demonstrates
emporal changes of EF, global T, CV segmental T,
lobal , and CV segmental . Parallel significant temporal
hanges can be seen only between EF and CV segmental ,
ot between EF and CV segmental T or global . The
ormalization for heart rate was performed using Bazett’s
ormula. In the absence of normalization, global T were as
ollows: volunteers at enrollment, 339  24 ms; IDC patients
aseline; middle panels  1 month; right panels  6 months. (Bottom) Myocar-
time from electrocardiographic peak R wave to peak systolic strain was 83 mss  b
elay int baseline, 386 38 ms; IDC patients at 1 month, 388 43
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Resynchronization With Beta-Blockers February 20, 2007:778–83s; and IDC patients at 6 months, 386  45 ms. Global T
as significantly lower in volunteers at enrollment compared
ith IDC patients at baseline (p  0.0005), at 1 month (p 
.0015), and at 6 months (p 0.0024), respectively. Global T
as similar between IDC patients at all 3 time points.
oefficient of variation segmental T was as follows: volunteers
t enrollment, 7  3%; IDC patients at baseline, 17  4%;
DC patients at 1 month, 15  5%; and IDC patients at 6
onths, 14  5%. Coefficient of variation segmental T was
ignificantly lower in volunteers at enrollment compared with
DC patients at baseline (p  0.0001), at 1 month (p 
.0001), and at 6 months (p  0.0010), respectively. In
atients with IDC, there was a significant decrease in CV
egmental T from baseline to 1 month (17 4% vs. 15 5%,
espectively, p  0.02), and from baseline to 6 months (17 
% vs. 14  5%, respectively, p  0.03).
Intraobserver and interobserver variability for segmental
 measurement was 2.9% and 6.9%, respectively. Intraob-
erver and interobserver variability for segmental  was 8.8%
nd 12.3%, respectively.
iscussion
ur data demonstrate that beta-blocker therapy induces
ignificant reductions in intraventricular dyssynchrony in
ilated cardiomyopathy patients with heart failure and
ormal QRS. Beta-blocker therapy is associated with an
arly (1 month) increase in regional systolic function (in-
reased global ) and a delayed decrease in mechanical
yssynchrony (decreased CV). Improvements in LVEF
nd reverse remodeling are coincident with reductions in
echanical dyssynchrony. Reduction in ventricular dyssyn-
hrony may be one of the mechanisms underlying the
eneficial effects of beta-blockers in HF.
Intraventricular and interventricular dyssynchrony have
merged as important mechanisms contributing to the
rogression of heart failure and ventricular remodeling
2,3). Their emergence has resulted in CRT becoming a
ignificant alternative in HF refractory to medical therapy in
atients with evidence of abnormal conduction. Beta-
lockers such as carvedilol are a critical component of HF
herapy. However, the interaction between beta-blockers
Ejection Fraction and Strain Echocardiographic
Table 3 Ejection Fraction and Strain Echoca
Volunteers (n  15)
LVEF (%) 63 5
Global T (ms) 348 24
CV segmental T (%) 7 3
Global  (%) 18.5 1.3
CV segmental  (%) 14 3
*p  0.05 when compared with baseline value.
CV segmental T  coefficient of variation of segmental T of 12
segments; LVEF  left ventricular ejection fraction; global T  avera
 values over 12 segments; IDC  idiopathic dilated cardiomyopathy;
Volunteers  healthy volunteers matched for age.nd dyssynchrony is uncertain. Furthermore, the effects of aeta-blocker therapy on regional and global cardiac me-
hanics have not been previously examined. Carvedilol
herapy has favorable effects on ventricular function, ven-
ricular remodeling, heart failure symptoms, morbidity, and
ortality (11–15). Although the precise mechanisms un-
erlying these favorable effects have not been fully clarified
t the whole heart level, several possible mechanisms include
eduction of heart rate and/or afterload (16), alleviation of
dverse neurohormonal effects (17), and antiapoptotic ef-
ects (18). To define the effects of carvedilol therapy on
ardiac mechanics and dyssynchrony, we used tissue
oppler-derived strain echocardiography to interrogate re-
ional and global myocardial function.
Tissue Doppler echocardiography and TDE-derived SE
epict regional displacement and deformation (19,20). Both
echniques have been extensively validated in the experi-
ental and clinical setting (21–23). Because mechanical
ynchrony cannot be assessed adequately via conventional
chocardiography, TDE and SE have become the mainstays
f dyssynchrony interrogation. Detailed descriptions of SE
ave been previously published (20). Although most data
egarding cardiac dyssynchrony have been generated using
DE, SE offers some advantages. Strain imaging is less
usceptible to translational motion and tethering artifacts
nd may be useful in subjects with extensive wall motion
bnormalities. Moreover, SE is superior to TDE in regional
unction analysis and was therefore more appropriate to
ccomplish our study objectives (10).
Our data demonstrate that carvedilol therapy significantly
ncreases regional and global contractility as evidenced by an
ncrease in  and EF. Our data also clarify the changes in
egional and global cardiac mechanics that potentially un-
erlie the improvements in cardiac function seen from
arvedilol therapy. Early after initiation of carvedilol therapy
here appears to be an increase in regional contractility.
hese regional changes in systolic function may be ex-
lained by previously demonstrated restoration of the bio-
ogical properties of the cardiac myocyte by carvedilol,
ncluding the reversal of high-energy phosphate production
nd normalization of calcium handling (24–27). Improve-
ent of impaired coronary flow reserve by carvedilol may
raphic Data
IDC patients (n  15)
aseline 1 Month 6 Months
28 6 31 7 37 10*
55 51 423 59* 415 50*
17 4 15 5* 14 5*
.2 1.8 10.4 3.9* 12.0 3.2*
44 12 47 22 33 15*
nts; CV segmental   coefficient of variation of segmental  of 12
mental T values over 12 segments; global   averaged segmental
ntal T values  time to peak systolic strain corrected for heart rate;Data
rdiog
B
4
8
segme
ged seglso contribute to the recovery of LV function (28).
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February 20, 2007:778–83 Resynchronization With Beta-BlockersHowever, it appears that the early increments in local
ontractility do not translate into an increment in global
unction, as seen by the absence of a significant change in
F. On the other hand, an improvement in intraventricular
ynchrony, that occurs several months later, is associated
ith an increase in EF. The increase in EF and reduction in
yssynchrony is coincident with echocardiographic evidence
f reverse remodeling. The coordinated LV contraction
esulting in improved chamber efficiency and reduced myo-
ardial energy consumption observed in CRT also may
nderlie the global LV function improvements found with
he use of carvedilol (29,30). Our data concerning resyn-
hronization and reverse remodeling are concordant with
hose reported from CRT studies (4,5).
tudy limitations. We excluded patients with ischemic car-
iomyopathy. The effects of beta-blockers may be significantly
ifferent between patients with IDC and with ischemic car-
iomyopathy. We only included IDC patients with QRS
idth120 ms in this study. The effects of beta-blockers on
yssynchrony may be different in patients with more signif-
cant conduction disease (e.g., QRS 120 ms) and in
atients with ischemia and/or significant myocardial scar.
onclusions. Beta-blocker therapy stimulates increments
n local contractility and reduction of intraventricular dys-
ynchrony. To our knowledge, this is the first report of
ardiac resynchronization by medical therapy. Increased
egional systolic function followed by cardiac resynchroni-
ation potentially underlies the beneficial effects of beta-
lockers in heart failure.
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